Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 449-456

  Pomares, Xavier ^a   Montón, Concepción ^a   Espasa, Mateu ^a   Casabon, Jordi ^a   Monsó, Eduard ^a,b   Gallego, Miguel ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Azithromycin; Chronic obstructive pulmonary disease; Exacerbation; Macrolides

Indexed keywords

AZITHROMYCIN; ANTIINFECTIVE AGENT;

AGED; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM IDENTIFICATION; BRONCHUS SECRETION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CHI SQUARE DISTRIBUTION; DRUG ADMINISTRATION; HOSPITALIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SPAIN; SPUTUM; TIME;

ADMINISTRATION, ORAL; AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPAIN; SPUTUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856593056     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hurst JR, Vestbo J, Anzueto A, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128-1138.
2. Soler-Cataluna JJ, Martínez MA, Román P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925-931.
3. Moreno A, Belmonte Y, Gallego M, Pomares X, Real J. [Causes of death and risk factors for mortality in patients with severe chronic obstructive pulmonary disease.] Arch Bronconeumol. 2009;45:181-186. [Spanish.]
4. Monsó E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med. 1995; 152:1316-1320.
5. Kunisaki KM, Niewoehner DE. Antibiotic prophylaxis for chronic obstructive pulmonary disease: Resurrecting an old idea. Am J Respir Crit Care Med. 2008;178:1098-1099.
6. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157:1829-1832.
7. Southern K W, Barker PM, Solis A. Macrolide antibiotics for cystic fbrosis. Cochrane Database Syst Rev. 2004:CD002203.
8. Clement A, Tamelet A, Leroux E, Ravilly S, Fouroux B, Jais J P. Long-term effects of azithromycin in patients with cystic fbrosis: A double blind, placebo controlled trial. Thorax. 2006;61:895-902.
9. Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immuno-modulatory medications: Proposed mechanisms of action. Pharmacol Ther. 2008;117:393-405.
10. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fbrosis: A randomised trial. Thorax. 2002;57:212-216.
11. Saiman L, Marshall BC, Mayer-Hamblett N, et al; Macrolide Study Group. Azithromycin in patients with cystic fbrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA. 2003;290:1749-1756.
12. Gan WQ, Man S F, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic infammation: A systematic review and a meta-analysis. Thorax. 2004;59:574-580.
13. Suzuki T, Yanai M, Yamaya M, et al. Erythromycin and common cold in COPD. Chest. 2001;120:730-733.
14. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178:1139-1147.
15. Albert RK, Bailey WC, Casaburi R, et al. Chronic azithromycin decreases the frequency of chronic obstructive pulmonary disease exacerbations. Abstract A6416 presented at the American Thoracic Society Congress, May 13-18, 2011, Denver, CO.
16. Cobos-Trigueros N, Ateka O, Pitart C, Vila J. [Macrolides and ketolides.] Enferm Infecc Microbiol Clin. 2009;27:412-418. [Spanish.]
17. Flume PA, O'Sullivan B P, Robinson KA, et al. Cystic Fibrosis Foundation. Pulmonary Therapies Committee Cystic fbrosis pulmonary guidelines: Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176:957-969.
18. Vendrell M, de Gracia J, Olveira C, et al. [Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery.] Arch Bronconeumol. 2008;44:629-640. [Spanish.]
19. Pomares X, Monton C. Respiratory day hospital: What have we learned? Med Clin (Barc). 2011;136:454-455.
20. Smith IE, Jurriaans E, Diederich S, Ali N, Shneerson J, Flower CDR. Chronic sputum production: Correlation between clinical features and fndings on high resolution computed tomographic scanning of the chest. Thorax. 1996;51:914-918.
21. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117:398-401.
22. Anthonisen NR, Manfreda J, Warren CPW, Hershfeld ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
23. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256-1276.
24. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
25. Sethi S, Jones P W, Theron MS, et al; PULSE Study Group. Pulsed moxifoxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial. Respir Res. 2010; 11:10.
26. Huang BH, Wu CH, Hsia C P, Yin Chen C. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol. 2007;30:1579-1582.
27. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3: 331-350.
28. Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromy-cin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother. 1995;39: 1688-1690.
29. Parnham MJ, Culić O, Eraković V, et al. Modulation of neutrophil and infammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol. 2005;517:132-143.
30. Garcia-Vidal C, Almagro P, Romaní V, et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: A prospective study. Eur Respir J. 2009;34:1072-1078.
31. Miravitlles M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial fora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest. 1999;116:40-46.
32. Southern K W, Barker PM. Azithromycin for cystic fbrosis. Eur Respir J. 2004;24:834-838.
33. Tateda K, Ishii Y, Kimura S, Horikawa M, Miyairi S, Yamaguchi K. Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: A promising strategy or an oriental mystery? J Infect Chemother. 2007;13:357-367.